{"id":810849,"date":"2025-02-10T08:05:04","date_gmt":"2025-02-10T13:05:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocean-biomedical-announces-breakthrough-findings-in-egfr-mutant-lung-cancer-and-plans-for-fda-alignment-on-next-stage-development\/"},"modified":"2025-02-10T08:05:04","modified_gmt":"2025-02-10T13:05:04","slug":"ocean-biomedical-announces-breakthrough-findings-in-egfr-mutant-lung-cancer-and-plans-for-fda-alignment-on-next-stage-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocean-biomedical-announces-breakthrough-findings-in-egfr-mutant-lung-cancer-and-plans-for-fda-alignment-on-next-stage-development\/","title":{"rendered":"Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development"},"content":{"rendered":"
\n

\n Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest<\/strong>\n <\/p>\n

\n Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) — <\/strong>Ocean Biomedical (NASDAQ: OCEA) today announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC). Specifically, they demonstrate that Ocean\u2019s immunotherapy candidates provide synergy with the TKI therapies (gefitinib and osimertinib) to suppress tumor growth and progression. In addition, the paper\u2019s findings demonstrate that its proprietary cancer immunotherapy candidates have a remarkable ability to restore treatment sensitivity following development of osimertinib resistance. This breakthrough offers a potential paradigm shift in the treatment of Epidermal Growth Factor Receptor (EGFR)-mutant NSCLC and could expand treatment options for patients whose tumors are no longer responding to tyrosine kinase inhibitors.<\/p>\n

These findings, led by Ocean Biomedical\u2019s Scientific Co-founder Dr. Jack A. Elias in collaboration with researchers at Yale University and Brown University, were published in Translational Oncology<\/em> and mark the first description of the role of chitinase 3-like-1 (CHi3L1) in EGFR-mutant cancers. The research underscores the ability of Ocean Biomedical\u2019s novel antibody to suppress CHi3L1 activity, leading to significant tumor reduction and, crucially, the reversal of drug resistance in preclinical models.<\/p>\n

As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating preclinical studies<\/strong> to advance its immunotherapy program and will engage with the FDA<\/strong> this year to align on a regulatory pathway for first-in-human trials.<\/p>\n

\n Industry Momentum: Bispecific Antibodies Leading a \u2018Gold Rush\u2019 in Oncology<\/strong>\n <\/p>\n

Ocean Biomedical\u2019s advancements come at a time when the oncology field is shifting its focus towards bispecific antibodies<\/strong>, an innovative therapeutic class designed to target multiple cancer mechanisms simultaneously. Bispecific antibodies that target PD-1\/PD-L1 and VEGF have shown remarkable efficacy in recent clinical studies, with leading biotech and pharmaceutical companies rapidly investing in this space.<\/p>\n

\n Merck\u2019s recent $588 million acquisition of LaNova\u2019s LM-299, a PD-1\/VEGF bispecific antibody currently in early-stage clinical trials, underscores the high-value potential of this technology<\/strong>. Industry experts suggest that this wave of investments mirrors the early days of checkpoint inhibitors, highlighting the significant opportunity for Ocean Biomedical to position itself at the forefront of the next major oncology breakthrough.<\/p>\n

Ocean has also developed bispecific antibodies that combine its anti-CHI3L1 antibody and anti-PD-1 or anti-CTLA4. Studies with these bispecific antibodies have highlighted their impressive efficacy in suppressing tumor growth and progression in preclinical models of NSCLC, malignant melanoma and glioblastoma.<\/p>\n

\n Ocean\u2019s<\/strong>
\n \u00a0<\/strong>
\n Board<\/strong>
\n \u00a0<\/strong>
\n Chair<\/strong>
\n \u00a0<\/strong>
\n and Co-Founder Statement on Market Potential and Investor Opportunity<\/strong>\n <\/p>\n

\u201cOur latest findings open an exciting new avenue in lung cancer treatment by demonstrating a potential solution to osimertinib resistance, a critical unmet need for patients worldwide,\u201d said Dr. Chirinjeev Kathuria, Ocean\u2019s\u00a0Board\u00a0Chair\u00a0and Co-Founder<\/strong>. \u201cWith the industry shifting towards next-generation bispecific antibodies<\/strong>, Ocean Biomedical is strategically positioned to capitalize on this momentum in a variety of diseases including NSCLC, malignant melanoma and glioblastoma. The recent $588 million acquisition of LaNova\u2019s LM-299 validates the enormous market potential in this space, and we believe our innovative immunotherapy platform could drive significant value for both patients and investors.\u201d<\/p>\n

\n Expanding Therapeutic Applications<\/strong>\n <\/p>\n

The company\u2019s lead oncology program is poised for multiple therapeutic applications:<\/p>\n